Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Alpharma

This page shows the latest Alpharma news and features for those working in and with pharma, biotech and healthcare.

Lundbeck challenge to EC pay-for-delay ruling fails

Lundbeck challenge to EC pay-for-delay ruling fails

The four generics companies - Generics UK, Arrow, Alpharma and Ranbaxy - were fined around 52m, and those judgments have also been upheld by the General Court of the EU.

Latest news

  • UK government fines GSK over 'pay-for-delay' deals UK government fines GSK over 'pay-for-delay' deals

    Former Merck subsidiary Generics (UK) Ltd and Alpharma (acquired by Actavis in 2005) had been sued by GSK for patent infringement but the cases were dropped after the agreements to defer ... Now, Merck has been fined £5.8m with regard to the involvement

  • Lundbeck still 'appalled' by EC's €94m anti-competition fine Lundbeck still 'appalled' by EC's €94m anti-competition fine

    In total the EC hit eight companies, among them Alpharma (now part of Zoetis), Merck KGaA and Ranbaxy, with penalties worth a total of 146m, but Lundbeck with its 93.8m

  • EC fines pharma companies €146m for generic Celexa delay EC fines pharma companies €146m for generic Celexa delay

    Lundbeck, Alpharma, Merck KGaA, Generics UK, Arrow and Ranbaxy all hit. ... Celexa (citalopram) brand owner Lundbeck was subjected to the majority of the fine (almost 94m) with the remainder shared between several companies including Alpharma (now part

  • Nine pharma firms face EU fines over pay-for-delay deals Nine pharma firms face EU fines over pay-for-delay deals

    Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and Ranbaxy are all in line for financial penalties from the European Commission (EC), according to Reuters.

  • GSK accused of delaying generic Seroxat in UK GSK accused of delaying generic Seroxat in UK

    market. The OFT, which is the government department responsible for protecting consumers, said GSK infringed competition law by making “substantial payments” to Alpharma, Generics (UK) and Norton Healthcare to delay plans ... These payments were part

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • ParagonRx appoints ex-FDA medical officer ParagonRx appoints ex-FDA medical officer

    He began his pharmaceutical industry career at Organon, working in drug safety and medical knowledge management, before joining Alpharma as director of drug safety. ... He was promoted to senior director of medical affairs and then after King

  • Elite Pharma names Actavis VP as CEO Elite Pharma names Actavis VP as CEO

    Nasrat Hakim also has senior experience at Watson and Alpharma. Nasrat Hakim has left his international VP position at Actavis to join Elite Pharmaceuticals as president and CEO. ... His positions prior to Actavis include global VP, quality and

  • Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

    Other previous positions include senior VP commercial operations at pain specialists Alpharma Pharmaceuticals, VP marketing at Endo Pharmaceuticals and VP global strategy and commercial development at Mallinckrodt.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....

Quick links